SCHEMBL18192

SCHEMBL18192

Cn1cnc(CCl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5788100 0.98
SCHEMBL18110368 0.82 CYP2C9 (0.42)
SCHEMBL7402086 0.80 CYP2C9 (0.62)
SCHEMBL419467 0.78
SCHEMBL18411683 0.76
SCHEMBL246132 0.76
SCHEMBL5956451 0.76
SCHEMBL9602988 0.76
SCHEMBL743854 0.76
SCHEMBL906384 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111605852-A Recyclable loading box and preparation method thereof 苏州梅克兰包装材料有限公司 2020-09-01 CN claimed
EP-3089970-B1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-17 EP claimed
US-10085985-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-10-02 US claimed
EP-3089970-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-11-09 EP claimed
US-9428514-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-08-30 US claimed
WO-2015089075-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2015-06-18 WO claimed
US-20150158873-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-11 US claimed
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 WO disclosed
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 US disclosed
US-12281099-B2 Isoindolinone substituted indoles and derivatives as RAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-04-22 US disclosed
US-12257247-B2 Targeted degradation of VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-03-25 US disclosed
CN-114163437-B Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors 阿雷生物药品公司 2025-03-04 CN disclosed
US-4137237-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-01-30 US disclosed
US-4070475-A THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1978-01-24 US disclosed
US-4024271-A INHIBITORS OF HISTAMINE ACTIVITY SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-05-17 US disclosed
US-4022797-A PHARMACEUTICALS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-05-10 US disclosed
US-4018931-A INHIBITION OF H-2 HISTAMINE RECEPTORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-04-19 US disclosed
US-3950353-A HISTAMINE INHIBITORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1976-04-13 US disclosed
US-3950333-A HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1976-04-13 US disclosed